Q2 2026 saw strong ADHD portfolio growth, with JORNAY PM and AZSTARYS driving revenue gains and market share, while pain portfolio revenues were mixed due to pricing pressures. Full-year guidance was raised for AZSTARYS, and capital deployment remains disciplined.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.